Annual report pursuant to Section 13 and 15(d)

Stockholders??? Equity (Details Narrative)

v3.22.0.1
Stockholders’ Equity (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 03, 2021
Jul. 19, 2021
Jun. 19, 2021
Jun. 19, 2021
Jun. 18, 2021
Jul. 02, 2020
Jan. 14, 2020
Jan. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Jun. 19, 2020
Jun. 19, 2018
Subsidiary, Sale of Stock [Line Items]                        
Proceeds from Issuance Initial Public Offering             $ 50,000,000.0   $ 5,580,471 $ 46,704,210    
Research and Development Expense                 $ 14,583,283 $ 14,358,918    
[custom:NetProceedsFromPublicOfferingOfCommonStock]             $ 46,700,000          
Preferred Stock, Shares Authorized                   8,000    
Preferred Stock, Par or Stated Value Per Share                   $ 1,000    
Preferred Stock, Shares Outstanding                 0 4,361    
Common Stock, Shares, Outstanding                 216,269,450 200,113,431    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                 988,000      
Maximum [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Class of Warrant or Right, Exercise Price of Warrants or Rights                 $ 0.50      
Minimum [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Class of Warrant or Right, Exercise Price of Warrants or Rights                 $ 0.75      
Common Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Share Price             $ 1.55          
Stock Issued During Period, Shares, New Issues             32,260,000   3,023,147 32,260,000    
Conversion of Stock, Shares Converted   2,000                    
Conversion of Stock, Shares Issued   8,436,000                    
Series A Preferred Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Preferred Stock, Shares Authorized                 10,000,000      
Preferred Stock, Par or Stated Value Per Share                 $ 0.001      
Series A Preferred Stock [Member] | Designated [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Preferred Stock, Shares Authorized                 1,600,000      
Series B Preferred Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Preferred Stock, Shares Authorized                       8,000
Conversion of Stock, Shares Converted       4,218 143              
Preferred Stock, Shares Outstanding                 4,361 0    
Liquidity value and dividends description                 (i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021. Based on an accounting of the holders of record of Series B Preferred Stock on June 19, 2021 and 2020, the Company made dividend payments totaling      
Common Stock, Shares, Outstanding     1,687,200 1,687,200             1,365,600  
Series B Preferred Stock [Member] | Holders [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Debt Conversion, Converted Instrument, Shares Issued     8,436,000                  
Common Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Conversion of Stock, Shares Converted         286,000              
Aquarius Merger Agreement [Member] | Holders Of Aquarius Biotechnologies Inc [Member] | Unregistered Shares [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 1,500,000                      
Research and Development Expense $ 1,200,000                      
Share Price $ 0.80                      
Debt Instrument, Convertible, Conversion Price     $ 0.50 $ 0.50                
Underwritten Public Offering [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Proceeds from Issuance Initial Public Offering             $ 50,000,000.0          
[custom:NetProceedsFromPublicOfferingOfCommonStock]             $ 46,700,000          
Underwritten Public Offering [Member] | Common Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Stock Issued During Period, Shares, New Issues             32,600,000          
Underwritten Public Offering [Member] | Sales Agreement [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Sale of Stock, Consideration Received Per Transaction           $ 50,000,000            
Sale of Stock, Percentage of Ownership after Transaction           3.00%            
Sale of Stock, Number of Shares Issued in Transaction               3,023,147        
Proceeds from Issuance of Common Stock               $ 5,800,000        
Proceeds from Issuance Initial Public Offering               $ 5,600,000